🟢 Teva Pharma is trading 8.9% up in after-hours trading after Leerink initiated Outperform coverage with $45 target

Teva Pharma is trading at $40.13, up +8.90%, after Leerink Partners initiated coverage with an Outperform rating and a $45 price target on September 9, 2026.

• The analyst called Teva Pharma a growth story, citing commercial execution and pipeline opportunities.
• The nearly unchanged regular session points to concentrated extended-hours buying; no earnings release was identified for September 9, 2026.